Wells Fargo gave Alector an Overweight rating and a $7 share target, signaling a favorable view. The report adds no new company results, so the positive signal comes from one firm's opinion.
That view gives investors a favorable signal about Alector's shares. But the report offers no new information about its drugs, sales, or profits, so the support comes from one analyst firm's view alone.
Follow Alector, Inc. (ALEC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALEC